Lamassu BioTech

11/12/2025

🩺 𝐀𝐜𝐮𝐭𝐞 𝐩𝐚𝐧𝐜𝐫𝐞𝐚𝐭𝐢𝐭𝐢𝐬 𝐢𝐬 𝐚 𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐞𝐦𝐞𝐫𝐠𝐞𝐧𝐜𝐲 𝐭𝐡𝐚𝐭 𝐜𝐚𝐧’𝐭 𝐛𝐞 𝐢𝐠𝐧𝐨𝐫𝐞𝐝.

Every year in the U.S., ~𝟐𝟎𝟎,𝟎𝟎𝟎–𝟐𝟕𝟓,𝟎𝟎𝟎 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 are hospitalized with this sudden, life-threatening condition. Yet today, the standard of care remains 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐢𝐯𝐞 𝐨𝐧𝐥𝐲 — there are no approved drugs to directly address the underlying disease.

At Lamassu Biotech, we are working to change this.
👉 𝐑𝐀𝐁𝐈-𝟕𝟔𝟕, our investigational molecule, is designed to target the root mechanisms of acute pancreatitis.

Because patients — and their clinicians — deserve more than supportive care.

11/06/2025

p53 is one of the most famous genes in oncology — often called “The Guardian of the Genome.”

But what does that actually mean? It depends on who you ask:
For patients → the cell’s emergency brake
For doctors → DNA repair & tumor suppression
For scientists → MDM2 regulation shapes p53 activity

𝐅𝐚𝐜𝐭: 𝐓𝐏𝟓𝟑 𝐢𝐬 𝐭𝐡𝐞 𝐦𝐨𝐬𝐭 𝐟𝐫𝐞𝐪𝐮𝐞𝐧𝐭𝐥𝐲 𝐦𝐮𝐭𝐚𝐭𝐞𝐝 𝐭𝐮𝐦𝐨𝐫 𝐬𝐮𝐩𝐩𝐫𝐞𝐬𝐬𝐨𝐫 𝐢𝐧 𝐡𝐮𝐦𝐚𝐧 𝐜𝐚𝐧𝐜𝐞𝐫𝐬 (~𝟓𝟎%).

What’s fascinating is how versatile p53 really is:
🧬 It’s not just about stopping damaged cells — p53 can trigger apoptosis, senescence, or even metabolic reprogramming, depending on the context.
📚 More than 90,000 scientific papers mention p53 — making it one of the most studied proteins in biology.
💊 Despite this, directly targeting p53 in drug development has been notoriously difficult (so-called “undruggable target”) — but new strategies like MDM2 inhibitors or p53 reactivators (e.g. APR-246/eprenetapopt) are showing promise.
⚡ A quirky fact: p53 wasn’t initially discovered as a tumor suppressor — early studies mistakenly thought it was an oncogene because of the mutant forms found in cancers.

In short → p53 is less of a single switch, and more of a network hub orchestrating the cell’s fate.

11/03/2025

Lamassu Biotech today announced a significant clinical milestone in its Phase 1/2a trial investigating SA53, a first-in-class, small-molecule MDM2 inhibitor. According to data reviewed to date, there have been no serious or dose limiting adverse events, and SA53 has thus far demonstrated a favorable safety and tolerability profile. The therapy is currently advancing into higher-dose cohorts for the treatment of adult patients with solid tumors.

The ongoing Phase 1/2a trial, conducted in collaboration with the National Institutes of Health (NIH) and Cleveland Clinic, is designed to determine the safety, tolerability, pharmacokinetics, and preliminary efficacy of SA53. The therapy is being investigated in adult patients with sarcoma and other solid tumors who possess the p53 wild-type gene and who currently have limited therapeutic options.

Read the full announcement here: https://www.lamassubiotech.com/2025/11/03/sa53-mdm2-inhibitor-lamassu-biotech-reports-significant-progress-and-favorable-safety-profile-in-phase-1-2a-clinical-trial/

10/29/2025

Lamassu BioTech co-founders Gabi Hanna MD. and Dr. Rabi Hanna, who were both recognized among the most influential leaders shaping the future of health care by Business, recently discussed their visionary approach to developing novel oncology therapies and work to accelerate hope and healing for patients facing rare cancer diagnoses and other unmet patient needs.

🎥 WATCH the full interview with Jennifer Keirn from Crain's Content Studio HERE: https://www.crainscleveland.com/crains-content-studio/cleveland-brothers-advance-innovation-lamassu-biotech

10/28/2025

We are proud to share that Lamassu BioTech CEO Dr. Gabi Hanna MD. and co-founder Dr. Rabi Hanna have been named “Notable Leaders in Health Care Technology 2025” by Business. This prestigious recognition highlights top influential and innovative leaders shaping the future of Northeast Ohio across all healthcare sector. Gabi and Rabi's visionary leadership and commitment to innovation and patients continue to drive meaningful progress to bring new therapy, hope, and healing to patients.

Read Crain’s full feature here:https://www.crainscleveland.com/awards/notable-leaders-health-care-technology-2025

10/06/2025

“For those in the field of drug development, the desire to expedite the delivery and implementation of new treatments is tempered by an important but lengthy process created to ensure the efficacy and safety of any new protocol…Standing out in the crowd requires four important components: entrepreneurial thinking, accelerating innovation, financial considerations, and a commitment to science.” – Lamassu BioTech CEO Gabi Hanna MD.’s latest column is now live on Drug Discovery Online.

Standing out in the drug development crowd requires entrepreneurial thinking, accelerating innovation, financial considerations, and a commitment to science.

09/22/2025

Nearly 2 million Americans receive a cancer diagnosis each year. But, as this personal narrative in The Wall Street Journal notes, “Federal agencies and researchers have traditionally—and understandably—focused on more common cancers that affect larger numbers of people, often leaving the rare ones, at least until recently, with few treatment options or sometimes even guidelines for treatment.”

At Lamassu BioTech our novel therapy SA53, a genetically targeted therapy that targets the MDM2 protein in p53 wild-type sarcomas, is working to bring hope to those some of the deadliest cancers. SA53 has the potential to be a critical step to move beyond conventional chemotherapy to targeted therapy that brings hope and healing to millions who suffer from stubborn cancers that don’t respond to conventional treatments and to reduce the toxicity of cancer treatments.

After an unthinkable diagnosis, a Journal editor learned how challenging it is to find treatment and support for a rare disease—and discovered reasons for hope.

09/18/2025

“Drug development is too costly, too slow, and too often unsuccessful. I believe we must do better. To stay globally competitive, we need smarter processes, stronger collaboration, and bold change. Patients can’t afford for us to wait.” – Lamassu Biotech CEO Gabi Hanna on the Building Biotechs Podcast



📺Full interview on YouTube:
https://www.youtube.com/watch?v=ob86ZAszc-

09/15/2025

Lamassu BioTech CEO Gabi Hanna MD. is featured on the Building Biotechs Podcast with Carina Clingman, PhD, highlighting the importance of accelerating drug development responsibly.

Acceleration is not about recklessness. It is about creativity and responsibility. Smarter trial design and fast, clear, and transparent engagement with the FDA can create new models that deliver therapies to patients faster and safer. Patients benefit most when knowledge flows responsibly, not slowly.

🎥 Full interview on YouTube: https://www.youtube.com/watch?v=ob86ZAszc-s

09/12/2025

Every day we delay, patients suffer. In the U.S. alone, 50 people die daily from acute pancreatitis, and hundreds more live with permanent complications. At Lamassu, we believe bringing treatments to patients faster isn’t just innovation, it’s a moral duty. When we align science, safety, and urgency, we save lives.



🎥 Full interview with Carina Clingman, PhD: https://www.youtube.com/watch?v=ob86ZAszc-s

09/10/2025

At this week’s 14th annual Summit in , Lamassu a MD., took part in an thought-provoking panel discussion about how incorporating the full spectrum of patient data can improve clinical outcomes and support predictive analysis.

Along with the panel discussion, Dr. Hanna had productive discussions with King Faisal Specialist Hospital & Research Centre Björn Zoega, and Ambassador Dr. Deborah Birx, the CEO of Armata Pharmaceuticals, Inc. and the former response coordinator for the White House Coronavirus Task Force under President Trump, among other dignitaries. C3 International’s summits continue do a tremendous job bolstering between the US and the Arab world to improve the future of healthcare.

09/03/2025

Season three of the Building Biotechs Podcast with Carina Clingman, PhD, kicks off today with Lamassu Biotech CEO Gabi Hanna MD. Dr. Hanna shared his thoughts on why an entrepreneurial mindset can be a benefit in an industry that typically follows a traditional development model, the patient-centric mission of Lamassu Biotech, as well as the moral imperative to accelerate drug development when combatting rare diseases. Click the link below to listen now to this exciting episode of the Building Biotechs Podcast.

For our first episode of season three, I sat down with Gabi Hanna, MD, CEO and co-founder of Lamassu Biotech, where he leads the development of innovative t...